z-logo
open-access-imgOpen Access
Research Use Exemptions to Patent Infringement for Drug Discovery and Development in the United States
Author(s) -
A. A. Russo,
John R. Johnson
Publication year - 2014
Publication title -
cold spring harbor perspectives in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.853
H-Index - 105
eISSN - 2472-5412
pISSN - 2157-1422
DOI - 10.1101/cshperspect.a020933
Subject(s) - scope (computer science) , food and drug administration , business , liability , drug development , patent infringement , patent law , law , law and economics , drug approval , drug , risk analysis (engineering) , political science , pharmacology , medicine , economics , intellectual property , computer science , finance , programming language
Experiments with patented compounds or processes are sometimes necessary for Food and Drug Administration approval of a small-molecule drug, biologic, or medical device. The law exempts certain research and development activities using these patented compounds or processes. The two exemptions are (1) a judicially created exemption developed through case law and (2) an exemption created by the Hatch-Waxman Act (the "safe harbor" provision). This article analyzes the history of these exemptions and how the courts have interpreted their scope and provides future perspectives on protecting research and development activities from liability.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom